Werkgroep Cardiologische centra Nederland English

dal-GenE (Includerend)

A Phase III, Double-blind, Randomized Placebo-controlled Study to Evaluate the Effects of Dalcetrapib on Cardiovascular (CV) Risk in a Genetically Defined Population With a Recent Acute Coronary Syndrome (ACS): The Dal-GenE Trial

Middel
dalcetrapib
Populatie
acuut coronair syndroom
Fase
III
Jaar aanvang
2015
Meer informatie
ClinicalTrials.gov

Studiedirecteur

drs. H.P. Swart (Cardioloog)
Sneek, D&A Research and Genetics